Lonza, a leading biotech manufacturing giant, showcased impressive growth in the first half of 2025, with its Vacaville facility playing a pivotal role in driving success. The company’s earnings report highlighted the Vacaville site as a key contributor to robust gains in its biologics division. Despite some challenges in the U.S.
market, Lonza remains confident in its ability to navigate uncertainties and support its customers effectively. With a strategic focus on being a preferred CDMO partner and a commitment to delivering exceptional results, Lonza’s global network and cutting-edge technologies continue to set it apart in the industry. The acquisition of the Genentech facility in Vacaville and significant investments in modernizing operations underscore Lonza’s dedication to innovation and growth.
Read more from thereporter.com